Showing 3461-3470 of 5773 results for "".
- SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenseshttps://modernod.com/news/sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technology-spectacle-lenses/2481552/SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Me
- RetinAI Partners with Boehringer Ingelheim to Advance Treatments for Patients with GA Using Artificial Intelligencehttps://modernod.com/news/retinai-joins-forces-with-boehringer-ingelheim-to-advance-novel-treatments-for-patients-with-ga-using-artificial-intelligence/2481550/RetinAI Medical has announced a new partnership with Boehringer Ingelheim, which will combine RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases with the goal of improving patient outcomes in geographic atrophy (GA).<
- CooperVision Seeks Proposals for 2023 Science and Technology Awardshttps://modernod.com/news/coopervision-seeks-proposals-for-2023-science-and-technology-awards/2481549/CooperVision announced it is now accepting submissions for its 2023 Science and Technology Awards program. The program enables researchers around the world to explore new dimensions in vision care, with the goal of translating innovative ideas into practical solutions. Each year, Cooper
- Mina Sooch Replaced as CEO of Ocuphire Pharma; Claims No Cause was Givenhttps://modernod.com/news/mina-sooch-out-as-ceo-of-ocuphire-pharma-rick-rodgers-to-serve-as-interim-ceo/2481548/Ocuphire Pharma announced on Friday it has parted ways with Mina Sooch as CEO and President. Rick Rodgers, a board member since 2020, was appointed interim CEO and President. Ocuphire said it has retained an executive search firm to assist in identifying a permanent CEO.
- Ocugen to Present on Modifier Gene Therapy Platform at ARVO 2023https://modernod.com/news/ocugen-to-present-on-modifier-gene-therapy-platform-at-arvo-2023/2481547/Ocugen announced that the company will present on its modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis; OCU410 for the treatment dry age-related macular degeneration (dry AMD); OCU410ST for the treatment of St
- One Million Patients Measured on the Neurolens Measurement Devicehttps://modernod.com/news/one-million-patients-measured-on-the-neurolens-measurement-device/2481546/Neurolens announced that 1 million patients have been measured on the Neurolens Measurement Device, an eye tracking system that can identify eye misalignment as small as 0.01 prism diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record number
- Bausch + Lomb to Present New Data on Products and Pipeline Programs at ARVOhttps://modernod.com/news/bausch-lomb-to-present-new-data-on-products-and-pipeline-programs-at-arvo/2481545/Bausch + Lomb announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023. The presentations include results from the 12-m
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through Recycling Programshttps://modernod.com/news/bausch-lomb-reports-more-than-65-million-units-of-contact-lens-eye-care-and-lens-care-materials-recycled-through-one-by-one-and-biotrue-eye-care-recycling-programs/2481540/Bausch + Lomb announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent to the weight of three commercial-sized airplanes.
- CORE Demonstrates Advanced 3D Printing for Ocular Research at ARVO 2023https://modernod.com/news/core-demonstrates-advanced-3d-printing-for-ocular-research-at-arvo-2023/2481539/Scientists from the Centre for Ocular Research & Education (CORE) plan to unveil multiple advancements in 3D printing during the ARVO 2023 Annual Meeting in New Orleans. These innovations may widespread applications, with the potential to accelerate dev